Sarepta Therapeutics (AKA: AVI Biopharma Inc) Profile last edited on: 3/24/2022
NO Business Identifier is currently available for this company. Year Founded
1980Last Involved Year
2018Key People / Management
Christopher Nishan Garabedian -- President and Chief Executive Officer
Location Information
215 First Street Suite 7
Cambridge, MA 02142
Cambridge, MA 02142
| (857) 242-3700 |
| www.sareptatherapeutics.com |
Public Profile
Sarepta Therapeutics -- formerly AVI BioPharma -- remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The company's developmental stage program includes AVI-4658, which is in phase Ib stage of clinical trial for the treatment of duchenne muscular dystrophy. Its preclinical stage programs consist of AVI-6006 for the treatment of Dengue virus; and AVI- 7100 for the treatment of H1N1 influenza virus. AVI BioPharma's programs that are authorized to enter phase I studies include AVI-6002 for the treatment of Ebola virus; and AVI-6003 for the treatment of Marburg virus. It has strategic alliance with Charley's Fund, Inc.
Extent of SBIR involvement
Synopsis: Techseeker Business Condition
Headquartered
USAEmployment
103Revenue
$5.3MPublic/Private
Publicly TradedStock Info
NASDAQ : SRPTReceived SBIR $$
YesTechseeker firm in the news
There are no news available.
